SAN DIEGO & BERLIN–(BUSINESS WIRE)–Vividion announced that the first patient has been dosed in a Phase Ib combination clinical trial for VVD-214, an investigational oral WRN inhibitor.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
